Novo Holdings

Glycomine, Inc. is a biotech company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, the company addresses the significant unmet medical needs of patients suffering from rare diseases, of which approximately 7,000 exist globally, with a majority lacking FDA-approved treatments. Glycomine specializes in creating replacement therapies that combine substrates, enzymes, and proteins with advanced bio-nano materials. These therapeutics are designed to facilitate the targeted delivery of treatment to clinically relevant organs, thereby enhancing the efficacy of care for conditions characterized by metabolic disorders and protein misfolding.

Sparrow Quantum Aps. is a Danish company focused on advancing quantum technology through the development of light-matter interfaces. It specializes in creating deterministic single-photon sources, which are essential for various quantum applications. The company boasts the highest efficiency in on-chip single-photon sources globally, characterized by superior photon purity, indistinguishability, and outcoupling capabilities. This innovative technology is the culmination of over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which Sparrow Quantum holds exclusive licenses to key patents. By leveraging self-assembled quantum dots integrated with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interaction, providing clients with advanced solutions for their quantum technology needs.

Sylvan Inc. is a biotechnology company specializing in the production and distribution of mushroom spawns, including agaricus, pleurotus, and shiitake strains, as well as casing inoculum. Founded in 1946 and based in Kittanning, Pennsylvania, Sylvan has expanded its operations internationally, with production and sales facilities in multiple countries, including the Netherlands, France, Hungary, and South Africa. The company also offers disease control products and nutritional supplements for the mushroom industry. Additionally, Sylvan engages in solid-state fermentation technology, providing sustainable solutions for various sectors, including food, health, agriculture, and materials. With research and development facilities in the United States and France, Sylvan positions itself as an innovative partner for businesses seeking to enhance their growth through fungal biotechnology.

Tribune Therapeutics is a preclinical biopharmaceutical company dedicated to advancing novel therapies for fibrotic diseases. They focus on developing innovative medicines targeting the CCN protein family, which plays a crucial role in fibrosis development. Their pipeline aims to address a broad spectrum of fibrotic conditions, offering potential new treatment options for patients.

Supira Medical, Inc. is a medical technology company based in Campbell, California, focused on developing a percutaneous ventricular assist device (pVAD) designed for high-risk patients undergoing interventional procedures. This innovative device offers high-flow mechanical support during critical situations such as high-risk percutaneous coronary interventions (PCI) and cardiogenic shock. By assisting the heart's native pumping action, Supira Medical's solution enables patients with severe coronary artery disease or related comorbidities to safely undergo necessary interventions, thereby facilitating quicker recovery from heart-related issues. Founded in 2012 and originally known as Lumenblation Medical, Inc., the company rebranded in March 2016 to reflect its commitment to advancing cardiac care.

Hillstar Bio is a biopharmaceutical company focused on developing precision immunotherapies for treating autoimmune diseases. Its innovative approach selectively targets and depletes harmful immune cells, sparing healthy ones, to address specific disease mechanisms and reduce the risks associated with chronic broad immunosuppression. The company aims to provide durable relief and immune reset for patients with autoimmune conditions, addressing unmet medical needs.

Augustine Therapeutics N.V. is a biopharmaceutical company based in Gent, Belgium, focused on developing innovative therapies for patients suffering from Charcot-Marie-Tooth disease (CMT) and other neuromuscular disorders. Founded in 2019, the company is engaged in two drug discovery programs aimed at identifying novel selective HDAC6 inhibitors. These compounds are designed to prevent nerve degeneration and facilitate the repair of peripheral myelin and axons. Through its research and development efforts, Augustine Therapeutics seeks to enhance the quality of life for patients affected by these debilitating conditions.

Biocomposites Limited specializes in the development, manufacturing, and distribution of calcium compound devices aimed at regenerating and repairing bone and soft tissue. Founded in 1996 and located in Keele, United Kingdom, the company offers a range of innovative products including STIMULAN, a pharmaceutical-grade calcium sulfate for infection management; geneX, an absorbable synthetic bone graft material that accelerates bone growth; and Allogran-R, a calcium phosphate bone substitute providing an osteoconductive scaffold. Additionally, Biocomposites produces Bilok, a synthetic calcium composite used in ligament reconstruction, and Biosteon, a technology designed to enhance implant and bone integration. Their products are utilized in various medical applications, including musculoskeletal infections, bone and joint trauma, spine surgery, and sports injuries, enabling healthcare providers to deliver effective treatment solutions.

Callio Therapeutics specializes in the development of advanced antibody-drug conjugates (ADCs) for cancer treatment. Their focus is on creating multi-payload ADCs, which allow for the targeted delivery of drug combinations to tumor cells, potentially maximizing therapeutic benefits and improving patient outcomes.

Newleos Therapeutics is a stealth-mode biotechnology company focused on developing safer and more effective treatments for neuropsychiatric disorders, aiming to improve mental health outcomes.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.

Windward Bio is a clinical-stage biopharmaceutical company dedicated to enhancing outcomes for patients with advanced immunological diseases, focusing on severe respiratory conditions. The company is advancing a fully human monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 clinical trials. This antibody, administered subcutaneously, potently binds to the TSLP ligand, extending its half-life and silencing its effector functions. Windward Bio is also developing innovative bispecific programs for other immunological disorders, led by a team of experienced biopharmaceutical executives aiming to address significant unmet medical needs in this field.

AnaCardio is a clinical stage biopharmaceutical company focused on developing innovative drugs for the treatment of heart failure. The company's therapeutics aim to enhance the contractility of the heart muscle through a unique mechanism that utilizes a therapeutic peptide. This approach is designed to avoid common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, ischemia, or hypotension. By improving cardiac output safely, AnaCardio's drugs have the potential to enhance organ function, elevate quality of life, increase functional capacity, and lower the risks of hospitalization and mortality for patients suffering from heart failure.

Coave Therapeutics specializes in developing gene therapies for rare ocular and central nervous system (CNS) diseases. Their primary focus is creating treatments for rare retinal disorders using a recombinant adeno-associated virus vector, which delivers a functional copy of the PDE6B gene directly between photoreceptors and the retinal pigment epithelium to provide effective visual restoration.

Numab is a biotechnology company focused on developing antibody-based therapies for severe diseases like chronic inflammation and cancer. Its proprietary platform streamlines the discovery process by reducing randomness, predictably generating ready-to-develop multispecific biotherapeutics tailored to engage multiple targets simultaneously. This enables healthcare industries to access Numab's platform for innovative treatments in these areas.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Orbis Medicines is a biotechnology company focused on advancing drug discovery through its innovative macrocyclic chemistry and computational platform. The company specializes in high-throughput drug discovery, aiming to develop new therapeutics that can significantly improve patient outcomes. By leveraging its unique chemistry and advanced computational techniques, Orbis Medicines seeks to address challenging targets in areas with high unmet medical needs, thereby accelerating the process of bringing effective treatments to market.

SiteOne Therapeutics is a San Francisco-based company focused on developing innovative therapeutics and diagnostics aimed at treating acute and chronic pain. The company specializes in creating products that address the limitations of existing pain management therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids. Its lead therapeutic candidates are selective inhibitors of the voltage-gated sodium ion channel Naᵥ1.7, which is essential for the generation and conduction of pain signals. By targeting this specific channel, SiteOne Therapeutics aims to provide more effective and safer pain relief options for healthcare professionals and their patients, particularly in the treatment of neuropathic pain.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists designed to manage these conditions by reducing blood flow and lipid uptake in adipose tissue. Through its innovative approach, the company seeks to address significant health challenges associated with metabolic disorders.

ADCendo ApS is a biotech company focused on the development of innovative anti-cancer therapies, specifically through the creation of antibody-drug conjugates (ADCs). These conjugates are designed to target receptors that are overexpressed in various forms of cancer, addressing significant unmet medical needs in the treatment landscape. ADCendo's approach aims to enhance targeted therapy for patients suffering from conditions such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, among others. By developing new medicines that effectively target carcinomas—including breast, colon, pancreatic, prostate, ovarian, and renal cancers—ADCendo seeks to improve treatment outcomes for cancer patients.

Benchmark Genetics is a prominent company in aquaculture genetics, specializing in the development of genetic material for various species, particularly salmon, shrimp, and tilapia. With extensive experience from 30 applied breeding programs across 16 countries, the company is recognized as a leading provider of genetics services in the industry. Their approach is innovation-driven, utilizing advanced breeding technologies such as Quantitative Trait Loci (QTL) and Genomic Selection. Benchmark Genetics places significant emphasis on customer collaboration, fostering long-term partnerships with leading aquaculture businesses to enhance genetic improvements and develop new products. In addition to their genetic offerings, the company provides comprehensive technical support to ensure clients maximize the potential of their genetic resources. Their dedicated sales teams include technical specialists knowledgeable about their focus species and various production systems, including Recirculating Aquaculture Systems (RAS).

Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Kivu Biosciences, based in San Francisco, is a biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company aims to deliver superior therapeutics and rapidly advance transformative assets, operating discreetly while focusing on its innovative pipeline.

Based on our deep science and focused on patients in need.

Booster Therapeutics is a biotechnology company focused on developing innovative medicines aimed at addressing aging-related diseases. The company specializes in regulating cellular homeostasis, which involves restoring balance within cells to eliminate toxic accumulations. By targeting the cellular systems responsible for maintaining cellular health, Booster Therapeutics aims to create drug modalities that can prevent and treat various diseases associated with aging.

Stingray Marine Solutions AS is a Norwegian technology firm based in Oslo, specializing in innovative solutions for the aquaculture industry, specifically in the removal of sea lice from fish. Founded in 2010, the company has developed an advanced optical delousing system that employs camera vision and laser technology to detect and eliminate sea lice from salmon in net pens. This automated process enhances fish health management by minimizing the need for physical handling of the fish, thereby increasing productivity in salmon farming. Stingray Marine Solutions operates as a subsidiary of Beck Engineering AS and has its origins in the entrepreneurial vision of Esben Beck, who has been involved in technology development since 1999.

Convergent Therapeutics is a clinical-stage biotechnology company specializing in the development of radiopharmaceutical therapies for prostate cancer. The company's lead product, CONV 01-α, is a monoclonal antibody conjugated with the radioactive alpha particle emitter 225Ac, designed to bind specifically to the prostate-specific membrane antigen (PSMA). This innovative therapy allows for the internalization of the radioactive payload directly into prostate cancer cells, enhancing treatment efficacy. Developed through proprietary technology by Dr. Neil Bander at Weill Cornell Medicine, CONV 01-α is protected by multiple U.S. and foreign patents. If it receives FDA approval, it will become the first antibody to target a radioisotope for prostate cancer treatment and the first drug to utilize 225Ac in this context. Convergent Therapeutics aims to leverage its therapeutic platform to explore targeted combination strategies against validated and novel cancer antigens, ultimately enhancing treatment options for patients.

Route 92 Medical, established in 2015 and headquartered in San Mateo, California, specializes in the development of innovative medical devices for stroke treatment. Their flagship product is a stealthy catheter designed for rapid and efficient removal of blood clots during acute ischemic stroke, aiming to improve patient outcomes and enhance recovery. Additionally, the company offers a rapid aspiration thrombectomy system and an intra-cerebral implant delivery system, further expanding their capabilities in stroke care.

Elektrofi is a preclinical-stage company based in Boston, Massachusetts, focused on revolutionizing drug delivery to enhance patient experiences. Founded in 2016, Elektrofi specializes in a formulation system capable of processing a broad spectrum of therapeutic molecules, including large and complex proteins such as monoclonal antibodies, bispecifics, and fusion proteins. The company's technology aims to improve subcutaneous administration, enabling drug manufacturers to create innovative therapies that offer patients greater control over how they receive life-changing medicines.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Magenta Medical Ltd. is a privately held company founded in 2012 and headquartered in Kadima, Israel. The company specializes in developing innovative medical devices aimed at treating acute decompensated heart failure. Its primary product line includes a temporary venous catheter-based therapy and a self-expanding heart pump designed to address key issues associated with acute heart failure, such as renal venous congestion. By enabling cardiac specialists to more effectively manage fluid and salt removal, Magenta Medical's solutions aim to improve patient outcomes while safeguarding kidney function.

Draupnir Bio is focused on developing innovative cholesterol-lowering medications that aim to prevent heart blood clots more effectively than existing treatments. The company leverages a platform technology that explores the glycome to create novel therapeutics through advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. Draupnir Bio specializes in synthesizing, screening, and selecting potent heparan sulfate glycomimetic drug candidates that address cardiovascular, inflammatory, and infectious diseases. Additionally, the company is working on protein degraders that target extracellular disease proteins, which could potentially address a wide range of unmet therapeutic needs across various medical conditions, providing more convenient treatment options compared to traditional injectable therapies.

Asceneuron SA, established in 2012 and headquartered in Lausanne, Switzerland, is a biotechnology subsidiary of Merck KGaA dedicated to discovering and developing therapeutics for neurodegenerative disorders with high unmet medical needs. The company focuses on progressive supranuclear palsy, orphan tauopathies, Alzheimer's disease, and Parkinson's disease, aiming to provide effective treatments where none currently exist or are limited in their benefits. Asceneuron operates by targeting the underlying causes of these debilitating conditions, such as abnormal tau protein deposits, with the goal of developing orally bioavailable therapeutics that can improve patients' lives and address the growing healthcare burden posed by neurodegenerative diseases.

HepaRegeniX GmbH is a biopharmaceutical company based in Ulm, Germany, founded in 2016. It specializes in developing innovative therapies for acute and chronic liver diseases, focusing on restoring the regenerative capacity of hepatocytes. The company’s therapeutic approach is based on research led by Professor Lars Zender at the University Hospital Tübingen, which identified mitogen-activated protein kinase kinase 4 (MKK4) as a critical regulator of liver regeneration. HepaRegeniX is developing small-molecule inhibitors of MKK4, aiming to enhance liver regeneration even in severely diseased conditions. The company’s potential treatments may address various liver disorders, including nonalcoholic steatohepatitis.

MATR Foods is a food-tech startup focused on creating fungi-based food ingredients. The company specializes in transforming byproducts into healthy food options, utilizing mushrooms, vegetables, and fruits to develop nutritious dishes. MATR Foods emphasizes natural nutrition in its offerings, providing organic vegetables and stuffing for various food products, such as steaks and buns. The company's mission is to deliver healthy food alternatives that are free from additives and not over-processed, catering to consumers seeking wholesome and innovative culinary choices.

AgNext Technologies Private Limited is an AgTech company dedicated to enhancing food quality assessment through AI-based technologies. The company provides a comprehensive software-as-a-service (SaaS) platform tailored for agribusinesses, enabling instant and automated analysis of food quality. By integrating hardware and software solutions, AgNext facilitates on-the-spot evaluations, thereby improving transparency, safety, and trust in the agricultural value chain. Additionally, AgNext's agricultural sensing platform leverages precision and digital agriculture technologies, utilizing imagery and Internet of Things (IoT) devices. This allows farmers to receive timely updates via a mobile application for crop monitoring, analysis, and record-keeping.

ADCendo ApS is a biotech company focused on the development of innovative anti-cancer therapies, specifically through the creation of antibody-drug conjugates (ADCs). These conjugates are designed to target receptors that are overexpressed in various forms of cancer, addressing significant unmet medical needs in the treatment landscape. ADCendo's approach aims to enhance targeted therapy for patients suffering from conditions such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, among others. By developing new medicines that effectively target carcinomas—including breast, colon, pancreatic, prostate, ovarian, and renal cancers—ADCendo seeks to improve treatment outcomes for cancer patients.

Cargo Therapeutics is a clinical-stage biotechnology company focused on developing innovative CAR T-cell therapies to improve outcomes for cancer patients. The company aims to address the challenges faced by existing autologous CAR therapies, which are only curative for less than half of cancer patients and hindered by issues such as manufacturing limitations, supply challenges, and reimbursement barriers. Cargo Therapeutics is advancing next-generation cell therapies designed to enhance effectiveness, safety, and supply reliability. One of its key products, CRG-022, is a novel CAR T-cell candidate targeting CD22, an antigen present in a majority of B-cell malignancies, specifically designed to overcome treatment resistance. By pursuing these novel solutions, Cargo Therapeutics seeks to facilitate broader access to curative therapies and significantly improve the treatment experience for cancer patients.

CIRCTEC is a company specializing in pyrolysis technology to convert waste into renewable fuels and circular chemicals. It focuses on producing sustainable drop-in fuels and circular chemicals derived from end-of-life tires, addressing the significant waste generated annually in this sector. By operating at the intersection of innovation and technology, CIRCTEC aims to enhance sustainability within the chemical, petrochemical, and oil industries, contributing to a cleaner environment and promoting circular economy practices.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in the manufacturing of heavy-duty single-use plastic containers and packaging products designed for the transportation of liquids, particularly in the pharmaceuticals and biopharma sectors. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, to enhance fluid logistics processes and minimize the risk of leakage or bio-contamination. By providing tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid transport, addressing the specific needs of its clients in the pharmaceutical industry.

Bluejay Therapeutics is a private biopharmaceutical company dedicated to developing curative treatments for infectious diseases, with an initial focus on chronic Hepatitis B. This disease remains prevalent worldwide and has significant unmet medical needs. The company is pursuing two innovative approaches: fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. These therapies aim to reduce hepatitis B surface antigen levels and restore adaptive immunity, potentially achieving a functional cure for patients.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, established in 2021. The company specializes in developing an innovative immunotherapy platform aimed at treating various types of cancer. This platform utilizes bispecific domain antibodies to effectively target and eliminate tumor cells. Furthermore, it incorporates modular technology that enhances its ability to engage the body's innate immune response, thereby activating the complement component of the immune system. This approach not only focuses on cancer treatment but also has potential applications in addressing autoimmune diseases.

Reunion Neuroscience is a clinical-stage pharmaceutical company dedicated to developing therapeutic solutions for underserved mental health conditions. The company’s primary focus is on its lead asset, RE104, a proprietary serotonergic psychedelic compound designed as a fast-acting and durable antidepressant for patients experiencing postpartum depression and other mental health issues. Additionally, Reunion is advancing the RE200 series, which comprises compounds aimed at achieving more selective serotonin receptor activity with reduced psychoactivity, thereby broadening the potential applications for chronic treatment scenarios. The company seeks to address significant gaps in mental health care through innovative pharmacological approaches.

Reduced is a food production company focused on creating natural flavor enhancers from upcycled produce and organic surplus materials. By utilizing ingredients such as seaweed, shore crabs, and byproducts from egg-laying chickens and bull calf bones, Reduced aims to minimize food waste while providing consumers with sustainable, high-quality food products. The company’s approach not only promotes environmental responsibility but also enhances culinary experiences, making healthy and flavorful options more accessible in kitchens and homes.

Obsidian Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in developing next-generation cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Its innovative approach utilizes pharmacologic operating systems that enable precise control over protein activity within cells. This technology allows for the creation of adoptive cell therapies with novel functionalities, which can be regulated by treating physicians using simple and safe orally active medications. Through these advancements, Obsidian Therapeutics seeks to improve upon existing cell therapies and expand treatment options for a broader patient demographic.

Clasp Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapeutics. The company has created a platform that aims to enhance the ability of the immune system to recognize and eliminate challenging tumors associated with common driver mutations, irrespective of tumor type. By leveraging precision medicine, Clasp Therapeutics seeks to identify cancer-specific markers that allow for the targeted destruction of tumor cells, thereby improving treatment outcomes for patients with difficult-to-treat cancers.

Asgard Therapeutics is a private biotechnology company focused on developing innovative cancer immunotherapies through direct cell reprogramming technologies. Founded as a spin-off from Lund University, the company employs its proprietary TrojanDC technology to initiate immune responses by leveraging the biological properties of professional antigen-presenting cells. With a commitment to creating personalized and efficient gene therapy products, Asgard Therapeutics aims to expand its pipeline of off-the-shelf cancer treatments, particularly for patients with cancers that are resistant to traditional therapies. By activating tailored anti-cancer immune defenses, the company seeks to offer new therapeutic options for individuals in need of effective cancer treatment alternatives.

Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Orbis Medicines is a biotechnology company focused on advancing drug discovery through its innovative macrocyclic chemistry and computational platform. The company specializes in high-throughput drug discovery, aiming to develop new therapeutics that can significantly improve patient outcomes. By leveraging its unique chemistry and advanced computational techniques, Orbis Medicines seeks to address challenging targets in areas with high unmet medical needs, thereby accelerating the process of bringing effective treatments to market.

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

Manipal Hospitals, part of the Manipal Education and Medical Group, is a prominent player in India's healthcare sector, particularly recognized in South India. With a legacy spanning over five decades, it has evolved into the country's third largest healthcare group, operating a network of 15 hospitals and three primary clinics. The organization offers a wide range of multi-specialty healthcare services that cater to both Indian and international patients. Its comprehensive care includes both curative and preventive services, addressing medical issues from minor ailments to complex health challenges. Manipal Hospitals is dedicated to providing quality and affordable healthcare, making it a significant contributor to the healthcare landscape in India and beyond.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to bridge the gap between food, agriculture, and health by employing precision gene editing and breeding technologies, genomics, and data analytics. Through partnerships with stakeholders across the food systems value chain, Elo focuses on improving agricultural productivity, meeting nutritional demands, and addressing food security challenges. By replacing sugar and artificial sweeteners with healthier alternatives, Elo Life Systems empowers individuals to enjoy their favorite foods while promoting healthier lifestyles.

Cleveland Diagnostics is a commercial-stage company based in Cleveland, Ohio, focused on developing and commercializing innovative cancer diagnostic tests. Founded in 2013, the company specializes in creating non-invasive screening tools for various cancers, including prostate, breast, ovarian, lung, and certain neurological diseases. Their portfolio includes blood-based tests designed to enhance early detection and improve patient outcomes. Cleveland Diagnostics employs a proprietary solvent interaction analysis technology that examines protein biomarkers at a structural level, offering more precise insights into disease processes and enhancing test specificity. The company has established strategic collaborations with industry partners, such as Genomic Health, to advance its diagnostic capabilities.

Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment.

OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

Nalu Medical is an early-stage company based in Carlsbad, California, focused on developing innovative medical devices to enhance the treatment of chronic pain. Founded in 2014, the company has created a battery-free, micro-implantable pulse generator that is cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS). Nalu Medical's neurostimulation devices leverage neuromodulation technology to offer a variety of therapeutic options aimed at alleviating chronic pain, thereby improving the quality of life for patients.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective and safe options for managing chronic pain and hearing loss. Through its research and development efforts, Hoba Therapeutics seeks to deliver disease-modifying treatments that enhance the quality of life for patients suffering from neuropathic pain.

Doctor Anywhere is a Singapore-based telehealth company that offers a comprehensive digital platform for on-demand healthcare solutions. It provides quick access to a range of health and wellness services, allowing users to consult licensed medical professionals for diagnoses, medications, and e-prescriptions from anywhere and at any time. The platform is designed to be simple and convenient, catering to the evolving lifestyle preferences of modern users. By leveraging technology, Doctor Anywhere aims to enhance health outcomes and address contemporary healthcare challenges, making it easier for individuals to manage their health according to their specific needs.

EnergyRe is focused on advancing the clean energy transition through the development of energy infrastructure designed to decarbonize urban environments. The company specializes in building utility-scale projects, including onshore and offshore wind farms, solar generation facilities, and energy storage solutions. By enhancing the accessibility of affordable clean power, EnergyRe contributes to the modernization of electric grids, facilitating a more sustainable energy landscape.

NMD Pharma A/S is a clinical-stage biotech company based in Aarhus, Denmark, focused on developing small molecules to enhance neuromuscular transmission for the treatment of orphan motor neuron diseases, such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials aimed at alleviating the symptoms of myasthenia gravis. Utilizing a translational muscle electrophysiology platform, NMD Pharma leverages its expertise in muscle physiology to design innovative therapeutics that address significant unmet medical needs in neuromuscular disorders. The company aims to improve the quality of life and survival rates for patients affected by these debilitating conditions.

Terremoto Biosciences is a biotechnology company focused on the development and discovery of small-molecule medicines through innovative drug delivery systems. By utilizing lysine-based covalency, the company aims to optimize clinical profiles and enhance therapeutic benefits for various diseases. Terremoto's platform is designed to improve existing medications while also facilitating the creation of new therapies aimed at addressing critical healthcare challenges. Through its research and technology, Terremoto Biosciences strives to provide effective solutions for the treatment of devastating diseases, contributing to advancements in the healthcare sector.

MapLight Therapeutics is focused on discovering and developing innovative therapies for brain disorders. The company utilizes a unique platform that integrates single-cell transcriptomics with optogenetics, enabling the identification of novel drug targets. By leveraging these advanced technologies, MapLight aims to create effective treatments tailored to address complex neurological conditions. Founded in 2018 and based in San Francisco, California, the company is committed to advancing the understanding and treatment of brain disorders through its cutting-edge research and development efforts.

MinervaX is a biotechnology company focused on developing maternal vaccines to prevent infections caused by Group B streptococcus (GBS), which can lead to serious adverse pregnancy outcomes and life-threatening conditions for newborns. The company leverages a specific fusion protein that has shown promise in eliciting protective immunity against various clinically relevant GBS strains. By concentrating on this innovative vaccine approach, MinervaX aims to provide medical professionals with effective tools to safeguard newborns from bacterial infections, ultimately enhancing maternal and infant health outcomes.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for idiopathic pulmonary fibrosis (IPF) and other serious respiratory conditions. Headquartered in Seattle, Washington, with an additional office in San Diego, the company specializes in an inhaled formulation of pirfenidone, known as AP01. This formulation aims to enhance the amount of medication that reaches the lungs while minimizing side effects associated with oral treatments. Established in 2011, Avalyn Pharma is dedicated to improving care and outcomes for patients with severe respiratory diseases through its advanced therapeutic pipeline and novel inhaled therapeutics. Initially named Genoa Pharmaceuticals, the company rebranded to its current name in July 2017.

Acesion Pharma ApS is a biotechnology company based in Copenhagen, Denmark, focused on developing medical treatments for atrial fibrillation (AF), the most prevalent type of cardiac arrhythmia. Founded in 2011, Acesion Pharma specializes in creating SK channel inhibitors that aim to provide safe and tolerable chronic treatments for AF. These drugs work by inhibiting specific ion channels in heart cells, which are crucial for generating the electrical signals that regulate the heart's rhythm. The company's goal is to offer effective solutions for preventing the recurrence of atrial fibrillation and maintaining normal heart rhythm, thereby improving the quality of life for patients affected by this condition.

Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company based in Boston, Massachusetts, specializing in the development and commercialization of innovative therapies derived from novel tetracycline chemistry. The company’s lead product, NUZYRA, is a broad-spectrum antibiotic administered in both oral and intravenous forms, targeting adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Another significant product, SEYSARA, is designed for the treatment of moderate to severe acne vulgaris. Paratek has received Qualified Infectious Disease Product designation from the U.S. Food and Drug Administration for its lead antibiotic, reflecting its commitment to addressing urgent public health threats, including antibiotic resistance. The company maintains various collaboration agreements, including partnerships with Zai Lab and Allergan, as well as research agreements with academic institutions and military organizations, to further its mission in combating infectious diseases and exploring additional therapeutic areas such as multiple sclerosis and systemic inflammatory diseases.

HPNow is a company focused on developing innovative water and air treatment solutions through the on-site generation of hydrogen peroxide. Their technology allows for the efficient and autonomous production of hydrogen peroxide using only water, electricity, and air. With their compact HPGen hydrogen-peroxide generators, HPNow aims to replace conventional disinfectants, such as chlorine, which are increasingly regulated due to safety concerns. This transition not only enhances the safety of water, air, and food but also offers significant cost savings and logistical benefits for users. By providing a safer and eco-friendly alternative to toxic chemical disinfectants, HPNow seeks to reduce environmental impact while improving overall treatment efficacy across various industries.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

PT HaloDoc is a digital healthcare platform based in Jakarta, Indonesia, established in 2016. The company connects patients with a network of 19,000 licensed doctors and 1,000 certified partner pharmacies through its innovative communication platform. Users can engage with medical professionals via video calls, voice calls, and chat, allowing for real-time consultations and health advice. Additionally, HaloDoc facilitates the ordering of laboratory tests that can be conducted at home, enhancing the convenience of accessing healthcare services. The platform aims to simplify and improve the healthcare experience for patients by providing easy connections to doctors, clinics, and hospitals, as well as offering medical delivery services through its partner pharmacies.

Ellab is a manufacturer specializing in thermal validation and monitoring products, providing solutions that measure, record, and validate critical parameters in thermal processing. The company offers a diverse range of high-precision and modular systems, including wireless data loggers and thermocouple-based instruments, designed to support various applications such as sterilization, freeze-drying, environmental chambers, heat tunnels, and pasteurization. With a global presence, Ellab sells its products in over 65 countries, focusing on reducing the time-to-market and minimizing the risk of product loss for its clients.

Octave Health Group Inc. is a behavioral health provider based in New York that focuses on addressing the mental health needs of young urban professionals. Established in 2017, Octave offers therapy and coaching for a wide range of clinical conditions, including anxiety, depression, trauma, and relationship issues, as well as general emotional well-being concerns such as stress management and self-esteem. The company aims to create a proactive approach to emotional health, akin to the emphasis placed on physical fitness. Its services are designed to be easily integrated into clients' lives and are delivered by a team of experienced psychologists, therapists, and coaches. Octave's innovative model emphasizes accessibility and sustainability, setting a new standard for mental health care through comprehensive and personalized support tailored to individual client needs.

Ray Therapeutics is a biotechnology company focused on developing innovative optogenetic gene therapies aimed at treating patients with blinding diseases. The company is dedicated to advancing technology that facilitates the understanding and study of rare retinal diseases. By harnessing optogenetics, Ray Therapeutics aims to empower medical professionals to effectively cure and manage inherited retinal disorders, thereby improving the quality of life for affected individuals.

Sangon Biotech Co. is a biotechnology company founded in 2003 as a Sino-foreign joint venture, specializing in the research and development of chemical synthesis of DNA. Over the years, Sangon has established itself as a key player in the global biotechnology market, known for its expertise in DNA synthesis, sequencing, and gene synthesis. The company has invested significantly in its infrastructure, including a manufacturing and industrial base in Songjiang Industrial Park. Sangon offers a wide range of products and services, including molecular biology kits, biochemicals, synthetic genes, oligos, peptide synthesis, enzymes, and laboratory consumables. By providing affordable life science research tools and services, Sangon supports researchers in advancing basic research and product development in the life sciences field.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

ADCendo ApS is a biotech company focused on the development of innovative anti-cancer therapies, specifically through the creation of antibody-drug conjugates (ADCs). These conjugates are designed to target receptors that are overexpressed in various forms of cancer, addressing significant unmet medical needs in the treatment landscape. ADCendo's approach aims to enhance targeted therapy for patients suffering from conditions such as soft-tissue sarcoma, osteosarcoma, glioblastoma multiforme, and triple-negative breast cancer, among others. By developing new medicines that effectively target carcinomas—including breast, colon, pancreatic, prostate, ovarian, and renal cancers—ADCendo seeks to improve treatment outcomes for cancer patients.

AMSilk GmbH is a Munich-based company that specializes in the production of spider silk proteins and other biomaterials for a variety of industrial applications. Founded in 2008, AMSilk manufactures high-quality silk biopolymers that serve diverse sectors, including pharmaceuticals, cosmetics, and technical textiles. Its product offerings include BioShield-S1, a non-immunogenic spider silk film for protective coatings, as well as biosteel spider silk fibers. The company also develops a range of wound care products and surgical applications, such as the SanaSilk durable skin barrier. Additionally, AMSilk provides spider silk protein beads and coatings for medical technology, alongside nonwovens for filters, wound dressings, and specialty textiles. Utilizing a patented biotechnological process, AMSilk's materials are fully biodegradable under aerobic and marine conditions, promoting sustainability in various applications. The company collaborates with partners like Gruschwitz Textilwerke AG to enhance its product offerings.

Clever Care Health Plan, Inc. is a healthcare company that specializes in providing Medicare Advantage plans with a focus on integrating Eastern and Western medicine. Founded in 2018 and headquartered in Westminster, California, with an additional office in Arcadia, the company offers culturally sensitive healthcare solutions designed to meet the diverse needs of its members. Clever Care connects Medicare beneficiaries to a network of healthcare providers, including hospitals and multilingual doctors, ensuring that members receive care in a language they understand. The company emphasizes preventive treatments and offers a range of services, including acupuncture, herbal remedies, and exercises like tai chi and qi gong, as well as traditional treatments such as cupping and moxibustion, aiming to enhance both the physical and mental health of its members.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Chromologics is a Danish biotechnology company specializing in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company has created a fermentation-derived platform for producing novel bio-based color pigments. These colorants are designed to offer optimal stability in terms of pH and temperature, making them suitable for a wide range of food products. Chromologics aims to provide food producers with sustainable alternatives to traditional colorants, such as carmine, thereby enhancing the natural appeal of food while supporting a shift towards more environmentally friendly practices in the food industry.

Aquafortus specializes in non-thermal crystallization technology aimed at recovering clean water and crystallizing salts from high-salinity brines. The company addresses the treatment needs of various industries, including cooling towers, mining, oil and gas, inland desalination, and flue gas desulfurization from power generation. By significantly reducing energy consumption, Aquafortus enhances the economic viability of liquid transportation, wastewater management, and zero liquid discharge processes. This innovative approach enables clients to lower their operating expenses while effectively managing high-salinity waste.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Elo Life Systems is a biotechnology company dedicated to enhancing human health and wellness through innovative food solutions. The company aims to bridge the gap between food, agriculture, and health by employing precision gene editing and breeding technologies, genomics, and data analytics. Through partnerships with stakeholders across the food systems value chain, Elo focuses on improving agricultural productivity, meeting nutritional demands, and addressing food security challenges. By replacing sugar and artificial sweeteners with healthier alternatives, Elo Life Systems empowers individuals to enjoy their favorite foods while promoting healthier lifestyles.

Spruce Biosciences, Inc. is a biopharmaceutical company based in Daly City, California, specializing in the development and commercialization of innovative therapies for rare endocrine disorders. Founded in 2014, the company is primarily focused on its lead product candidate, tildacerfont, which is undergoing clinical trials for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH). Tildacerfont is being developed as a non-steroidal therapy aimed at improving disease management and reducing reliance on steroids for affected patients. Additionally, the company is exploring the use of tildacerfont for females with polycystic ovary syndrome. With a commitment to addressing the unmet medical needs of patients with rare endocrine conditions, Spruce Biosciences aims to enhance the quality of life for those who have been historically underserved by existing treatment options. The company also has a partnership with Eli Lilly and Company to explore further pharmaceutical applications of its compounds.

LePure Biotech, established in 2011 and headquartered in Shanghai, China, operates within the biotechnology and pharmaceutical sectors. The company specializes in the development and manufacturing of disposable biopharmaceutical process equipment and consumables, primarily focusing on products that facilitate the storage, transportation, filling, and leak detection of samples related to biosimilars, vaccines, and other biopharmaceutical applications. Its core offering is a disposable storage bag designed to meet the specific needs of these processes. Recently, LePure Biotech completed a B+ round of financing, which aims to fund the development of innovative products, establish a research and development center in the United States, enhance supply chain integration, and expand its R&D operations both domestically and internationally.

Evosep ApS is a Danish company specializing in clinical proteomics, aiming to enhance the efficiency and reliability of protein-based diagnostics. Founded in 2016 and based in Odense, Evosep develops advanced solutions such as the EVOSEP ONE separation tool and EVOTIP disposable trap columns, which facilitate the rapid and reproducible analysis of biological samples. By leveraging years of expertise in nano-UHPLC research and development, Evosep focuses on addressing the growing demand for high-throughput proteomics. The company's innovative technologies are designed to make sample separation ten times faster and a hundred times more robust than existing methods, which is essential for accurately diagnosing health conditions through biomarker analysis. Collaborating with leading scientists, Evosep is committed to transforming clinical diagnostics to improve patient care and quality of life.

Amolyt Pharma is a clinical-stage biotechnology company focused on developing peptide-based therapies for rare endocrine and metabolic disorders. The company is advancing several programs, including AZP-3601, a parathyroid hormone analog aimed at treating hypoparathyroidism by maintaining stable calcium levels in the blood. Additionally, Amolyt Pharma is developing AZP-3404, a peptide with a novel mechanism of action designed to restore fat and glucose metabolism. Through its innovative approaches, the company aims to provide effective solutions for patients suffering from critical and rare metabolic conditions.

Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Doctor Anywhere is a Singapore-based telehealth company that offers a comprehensive digital platform for on-demand healthcare solutions. It provides quick access to a range of health and wellness services, allowing users to consult licensed medical professionals for diagnoses, medications, and e-prescriptions from anywhere and at any time. The platform is designed to be simple and convenient, catering to the evolving lifestyle preferences of modern users. By leveraging technology, Doctor Anywhere aims to enhance health outcomes and address contemporary healthcare challenges, making it easier for individuals to manage their health according to their specific needs.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Roslin Technologies is an ag-tech and food tech company focused on enhancing protein production through innovative biotechnologies. The company specializes in animal stem cell research, having developed perpetually self-renewing, pluripotent stem cells, which are pivotal for the advancement of cultivated meat products for consumers. Roslin's intellectual property and technological platforms are designed to supply these cell lines and related media formulations to the cultivated meat sector. Additionally, the company aims to leverage its stem cell technology to create cell therapies that address incurable diseases in animals, thereby supporting the meat industry in reducing costs and accelerating market entry.

Kate Farms, Inc. is a company that specializes in producing plant-based meal replacement shakes and tube feeding solutions for both adults and children. Founded in 2011 and headquartered in Santa Barbara, California, with an additional office in Waltham, Massachusetts, the company focuses on developing formulas that prioritize easy digestion and nutritional quality. Utilizing organic, plant-based ingredients, Kate Farms' products are free from synthetic additives and common allergens such as dairy, soy, gluten, corn, and nuts. The offerings are designed to cater to a wide range of dietary and medical needs, serving patients with severe chronic diseases as well as those with less serious medical issues. Products are available through a network of retail stores across the United States and online, with options for both prescription and over-the-counter purchase.

MedGenome is a company focused on advancing global health through its sequencing genomics-based diagnostics and research platform. This platform utilizes genomics technologies, bioinformatics, computing, and big data analytics to explore the genetic underpinnings of various diseases, including cancer, metabolic disorders, eye disorders, and rare diseases. MedGenome offers high-end genetic diagnostic tests across multiple categories such as immuno-oncology, infectious diseases, reproductive health, and rare diseases. By leveraging the genetic diversity of large populations, the company aims to provide valuable insights that support the healthcare industry in understanding diseases at both genetic and molecular levels.

Vestaron Corporation is a developer and manufacturer of peptide-based biologic crop protection products, designed to enhance the safety, efficacy, and sustainability of agricultural practices. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides, including Spear-T for treating thrips in vegetables and ornamentals, Spear-Lep for fruits and field crops, and Leprotec for broader field use. The company is recognized for its commitment to addressing resistance issues in pests while ensuring safety for workers, beneficial organisms, and the environment. Vestaron has received several awards for its innovative biocontrol solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, reflecting its leadership in the field of sustainable agriculture.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for severe hematologic disorders. Founded in 2017, the company specializes in human genetics-based therapeutics that aim to improve red blood cell production in patients suffering from various hematologic diseases. Disc Medicine's pipeline includes therapeutic candidates targeting critical pathways involved in red blood cell biology, such as heme biosynthesis and iron homeostasis. Notable programs include bitopertin, which is being developed for conditions like erythropoietic porphyrias and Diamond-Blackfan anemia. Through its research and development efforts, Disc Medicine seeks to transform the lives of patients affected by these challenging disorders.

Inspirna is a clinical-stage biopharmaceutical company focused on developing innovative drug candidates that target essential drivers of cancer. Utilizing a discovery platform centered on RNA biology, Inspirna identifies novel cancer targets that contribute to tumor growth and disease progression. The company is advancing several first-in-class oral small molecules, including RGX-202, aimed at treating patients with RAS mutant colorectal cancer, and RGX-104, which is in development for small cell lung cancer and non-small cell lung cancer. Through its microRNA-based target discovery approach, Inspirna seeks to provide effective treatment options for cancer patients by employing targeted therapies that leverage small molecules and biologics.